Ganirelix Acetate is a gonadotropin-releasing hormone (GnRH) receptor antagonist, which is mainly used in clinical use in women undergoing assisted reproductive technology controlled ovarian stimulation regimens to prevent the premature appearance of luteinizing hormone peaks and to treat fertility disorders caused by this cause. The drug has the characteristics of few adverse reactions, high pregnancy rate, short treatment cycle, etc., and has obvious advantages compared with similar drugs in clinical practice, and has been marketed in many countries and approved for marketing in China in June 2013.